Standout Papers
- Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) (2016)
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (2017)
- The emerging role of immune checkpoint based approaches in AML and MDS (2017)
- Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) (2016)
- Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. (2017)
- Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. (2017)
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes (2018)
Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Cancer statistics, 2022
2022 Standout
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase
2015
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Cancer statistics, 2023
2023 Standout
Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma
2019
Extracellular DNA traps released by acute promyelocytic leukemia cells through autophagy
2016
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
2016
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
2019
Cancer statistics, 2017
2017 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Cancer Statistics, 2021
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Cytokines in CAR T Cell–Associated Neurotoxicity
2020
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
2020
Hydrophobic mismatch drives self-organization of designer proteins into synthetic membranes
2024 StandoutNobel
Pancreatic cancer
2020 Standout
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016
New treatment for acute myelogenous leukemia
2014
Clinical lessons learned from the first leg of the CAR T cell journey
2019
Genetic engineering of T cells for immunotherapy
2021
Hallmarks of aging: An expanding universe
2023 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
2018
A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
2018
Hepatocellular carcinoma
2021 Standout
Genetically engineered T cells for cancer immunotherapy
2019
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
2018
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
2023
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
2019
Gut microbiota modulation of chemotherapy efficacy and toxicity
2017 Standout
Neutrophil extracellular traps in immunity and disease
2017 Standout
A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses
2021
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
PROTAC targeted protein degraders: the past is prologue
2022 Standout
The gut microbiota influences anticancer immunosurveillance and general health
2018
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
2019
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
2022
The PI3K Pathway in Human Disease
2017 Standout
Defining trained immunity and its role in health and disease
2020 Standout
De novo design of tyrosine and serine kinase-driven protein switches
2021 StandoutNobel
Clinical relevance of tumour-associated macrophages
2022
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Hepatocellular carcinoma
2022 Standout
Cytokines in clinical cancer immunotherapy
2018
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
2020 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Head and Neck Cancer
2020 Standout
Acute Myeloid Leukemia
2015 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Bladder Cancer
2020 Standout
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
2019
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
2013
Cytokine Storm
2020 Standout
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
2020
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Gemtuzumab Ozogamicin: Back Again
2019
Cancer treatment and survivorship statistics, 2016
2016 Standout
How I treat refractory and early relapsed acute myeloid leukemia
2015
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
2015
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
2021
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014
Works of Naval Daver being referenced
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
2015
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
2018
Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies
2013
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
2014
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
2012
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Secondary mutations as mediators of resistance to targeted therapy in leukemia
2015
Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.
2021
The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia
2016
Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia
2014
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
2013
Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)
2014
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
2016
Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
2018
A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
2014
A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults
2017
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
2019
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
2018
Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
2014
Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome
2012
Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
2017